Back to the main directory
EarningsReview / Equity
- LISI - En phase d’atterrissage by MidCap Partners
- OVH Groupe - OPRA = davantage de dette, est-ce bien raisonnable ? by MidCap Partners
- VIDRALA: RDOS. 9MESES’24 (ANÁLISIS BANCO SABADELL) by Sabadell
- Evolution - Buy/SEK 1310 (1270): Worth playing the odds by Nordea
- Kjell Group - Hold: Another weak quarter; leverage is worrying by Nordea
- Trelleborg - Hold: Estimates hold up after Q3 results by Nordea
- Kongsberg Gruppen - Buy/NOK 1,300 (1,150): No end in sight by Nordea
- Mycronic - Buy/SEK 494 (490): Multiplex strength by Nordea
- Tietoevry - Hold: Tech Services divestment process advancing by Nordea
- INVEST SECURITIES - ALTEN : Excès de pessimisme après les annulations tardives - ACHAT, OC 148€ (vs 152€) by Invest Securities
- Addtech - Buy/SEK 355 (362): Growing well in a tough market by Nordea
- Swedish Orphan Biovitrum - Buy/SEK 389 (346): The growth story unfolds by Nordea
- Doing well in a more challenging environment by BNP Paribas Exane
- INVEST SECURITIES - DASSAULT SYSTEMES : Confirmation d'un ralentissement conjoncturel - ACHAT, OC 46€ by Invest Securities
- Coor Service Management - Hold: Lowering our dividend expectations by Nordea
- Q3 conference call feedback by BNP Paribas Exane
- Pulp: China hardwood prices inch lower, softwood step higher by BNP Paribas Exane
- MERCEDES BENZ GROUP: RDOS. 3T’24 (ANÁLISIS BANCO SABADELL) by Sabadell
- Median Technologies - Double-digit growth in Q3 by MidCap Partners
- Remy Cointreau SA - Naturally adjusts its ambitions. by MidCap Partners
- Scandi Standard - In ligne by MidCap Partners
- Groupe Guillin SA - Results under pressure, as expected by MidCap Partners
- BOL, FQM, FCX, NEM, VALE, STEEL US, NUE, X, CLF, SSAB by BNP Paribas Exane
- Cereno Scientific - CMD highlights a ‘rare’ portfolio refocus by Edison Investment Research
- Zalaris - Another quarter of records by Edison Investment Research